Immuneering Corporation - Class A Common Stock (IMRX)
1.9900
+0.0800 (4.19%)
Immuneering Corp is a biotechnology company that focuses on developing innovative therapeutics to treat various forms of cancer and other diseases through a proprietary platform that leverages insights from advanced computational biology and machine learning. By understanding the complexities of disease biology and the interactions within cellular pathways, Immuneering aims to design and optimize drug candidates that can target specific molecular mechanisms, thereby increasing the chances of successful outcomes in clinical settings. The company is committed to advancing precision medicine to improve the lives of patients with unmet medical needs.
Discover today’s top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens.
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate and 80% disease control rate.
Shares of Science Applications International Corporation (NYSESAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P 500 also fell, dropping, 0.64% to 5,117.35.
Shares of Jabil Inc. (NYSEJBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 500 also fell, dropping, 0.62% to 5,118.35.
Shares of Limbach Holdings, Inc. (NASDAQLMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Unlock the latest Phase 1 trial results for IMM-1-104 by Immuneering. Discover how 320mg and 240mg doses inhibit tumor progression and evaluate safety profiles.
